A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

Sjögren · Sjogren Disease · Sjogren's Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Cullinan Investigative Site, Orlando, Florida, United States

  • Cullinan Investigative Site, Memphis, Tennessee, United States

  • Cullinan Investigative Site, Plano, Texas, United States

  • Cullinan Investigative Site, Webster, Texas, United States

  • Cullinan Investigative Site, Salt Lake City, Utah, United States

  • Cullinan Investigative Site, Brest, France

  • Cullinan Investigative Site, Le Kremlin-Bicêtre, France

  • Cullinan Investigative Site, Strasbourg, France

  • Cullinan Investigative Site, Erlangen, Germany

  • Cullinan Investigative Site, Hanover, Germany

  • Cullinan Investigative Site, Roma, Italy